Federated Hermes, Inc. Prometheus Biosciences, Inc. Transaction History

Federated Hermes, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	SELL	$103.46 - $126.29 $601,309 - $733,997	-5,812 Reduced 1.11%	516,589 $55.4 Million
Q4 2022 Feb 13, 2023	BUY	$36.06 - $117.21 $7.29 Million - $23.7 Million	202,267 Added 63.18%	522,401 $57.5 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $9.02 Million - $18.9 Million	320,134 New	320,134 $18.9 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.